Pazopanib
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80071756
CAS NO.444731-52-6
Purity 99%
MDL NumberMFCD11616589
Molecular FormulaC21H23N7O2S
Molecular Weight437.526
| Category | Content |
|---|---|
| Generic Name | Pazopanib |
| Brand Name | Votrient |
| Chemical Formula | C21H23N2O3S·HCl |
| CAS Number | 386580-66-8 |
| Mechanism of Action | Pazopanib is a multi-tyrosine kinase inhibitor targeting VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, and other kinases. It inhibits angiogenesis and tumor growth. |
| Indications | – Treatment of advanced renal cell carcinoma.<br>- Treatment of advanced soft tissue sarcoma. |
| Dosage Forms | Tablets (200 mg) |
| Administration | – Usual dose: 800 mg once daily.<br>- Take at least 1 hour before or 2 hours after a meal. |
| Common Side Effects | – Fatigue, diarrhea, nausea, hypertension, hair color changes, weight loss. |
| Serious Side Effects | – Hepatotoxicity.<br>- QT prolongation.<br>- Cardiac dysfunction.<br>- Hemorrhagic events.<br>- Arterial and venous thrombotic events.<br>- Gastrointestinal perforation and fistula.<br>- Reversible Posterior Leukoencephalopathy Syndrome (RPLS). |
| Precautions | – Monitor hepatic function.<br>- Avoid strong CYP3A4 inhibitors.<br>- Use with caution in patients with cardiac or liver impairment.<br>- Not recommended during pregnancy. |
| Storage | Store at room temperature, protect from moisture. |
| Developer | GlaxoSmithKline |
| Approval Date | FDA approval in October 2009. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
